Das Arun 4
4 · Cabaletta Bio, Inc. · Filed Mar 2, 2026
Research Summary
AI-generated summary of this filing
Cabaletta Bio CBO Das Arun Receives 175,000-Share Award
What Happened
Das Arun, Chief Business Officer of Cabaletta Bio (CABA), was granted a derivative award covering 175,000 shares on 2026-03-02. The filing reports an acquisition at $0.00 (reported value $0), indicating an equity award/option-style grant rather than an open-market purchase or sale. The award does not result in immediate common‑share ownership until vesting/exercise.
Key Details
- Transaction date: 2026-03-02 (filing dated 2026-03-02) — appears timely.
- Grant: 175,000 derivative shares; reported price $0.00; total reported consideration $0.
- Shares owned after transaction: Not specified in the provided filing.
- Vesting (footnote): 25% vests on March 1, 2027; remaining 75% vests in 12 substantially equal quarterly installments thereafter, subject to continued service.
- Transaction code: A = grant/award/other acquisition (derivative).
Context
This is a common form of executive equity compensation (stock options or RSUs-like derivative award). Because it’s a derivative grant with multi-year vesting, it does not represent an immediate change in voting or selling power and should not be interpreted as a market buy/sell signal by itself.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-03-02+175,000→ 175,000 totalExercise: $3.30Exp: 2036-03-01→ Common Stock (175,000 underlying)
Footnotes (1)
- [F1]25% of the shares underlying this option shall vest and become exercisable on March 1, 2027, with the remainder vesting in twelve substantially equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date.